rabbit anti‐en1 (Absolute Biotech Inc)
Structured Review

Rabbit Anti‐En1, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti‐en1/product/Absolute Biotech Inc
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "ENGRAILED ‐1 transcription factor has a paracrine neurotrophic activity on adult spinal α‐motoneurons"
Article Title: ENGRAILED ‐1 transcription factor has a paracrine neurotrophic activity on adult spinal α‐motoneurons
Journal: EMBO Reports
doi: 10.15252/embr.202256525
Figure Legend Snippet: Triple RNAscope in situ hybridization showing Engrailed‐1 ( En1 ), Choline acetyltransferase ( ChAT ), and Calbindin‐1 ( Calb1 ) expression in the lumbar spinal cord. En1 is expressed in V1 interneurons, dorsal (V1 P ) and ventral (V1 R ) to the main ChAT ‐expressing motoneuron pool. Ventral interneurons correspond to Renshaw cells as shown by Calb1 expression. Scale bar: 500 μm. RT–qPCR of RNA from the lumbar enlargement at 4.5 and 16 months of age shows stable En1 expression in WT at both ages and a twofold reduction of expression in heterozygous mice. Unpaired two‐sided t ‐test. ** P < 0.005; *** P < 0.0005. n = 3. Values are mean ± SD. Triple staining EN1 IHC (green), En1 RNAscope ISH (red), and ChAT RNAscope (blue) demonstrating the double staining of En1 mRNA and protein (EN1) in the V1 interneuron population (left panel insets, arrowheads point toward examples of double‐stained V1 interneurons), and the presence of EN1 protein in large cells not expressing En1 mRNA (left panel) but expressing ChAT (right panel insets). Scale bar: 500, 30 μm for high magnification insets. Left: EN1 (red) detected with the LSBio antibody is localized in ChAT‐expressing neurons (green) in the ventral horns of the spinal cord. Right: EN1 signal is lost upon preincubation of the antibody with 1.5 M excess of recombinant hEN1. Scale bar: 50 μm. Left: Relative positions of the different oligonucleotides selected to genotype the E15 embryos and examples of the genotyping based on the combination of PCRs with the different pairs of primers. Right: Double ChAT/EN1 immunostaining demonstrating the co‐localization of the two proteins in the WT and the En1 ‐Het ventral cord and the absence of EN1 staining in MNs from En1 ‐KO embryos. Note that the staining is reduced in En1 ‐Het embryos, compared with WT embryos. Data information: These experiments were performed once. Source data are available online for this figure.
Techniques Used: In Situ Hybridization, Expressing, Quantitative RT-PCR, Staining, Double Staining, Recombinant, Immunostaining
Figure Legend Snippet: Western blots of spinal cord (SC) and ventral midbrain (VMB) extracts demonstrating that the 86/8 and LSBio antibodies recognize in both structures the same protein migrating with recombinant EN1 velocity. No staining is observed in the absence of primary antibody (left panel). This experiment was performed twice. Double staining of 3‐month‐old WT and En1 ‐Het ventral MNs with the anti‐ChAT antibody and the anti‐EN1 LSBio antibody at various dilutions. EN1 staining decreases with increasing dilutions of the antibody. The loss of staining is more rapid in En1 ‐Het than in WT mice. Scale bar = 50 μm. Data information: This experiment was performed once.
Techniques Used: Western Blot, Recombinant, Staining, Double Staining
Figure Legend Snippet: Analysis of the number of En1 +, Calb1 +, and ChAT + neurons (triple RNAscope). At 4.5 months, WT and En1 ‐Het mice show no difference in the number of cells expressing En1 , Calb1 , or ChAT . Unpaired two‐sided t ‐test. n = 5–6. Cresyl violet and ChAT staining of a ventral WT spinal cord at the lumbar level. Scale bar: 100 μm. Cresyl violet and ChAT staining at the lumbar level show no medium‐size (200–299 μm 2 ) cell loss (γMNs) and a decrease of about 50% in the number of large‐size (> 300 μm 2 ) cells (αMNs). Unpaired two‐sided t ‐test. ** P < 0.005; **** P < 0.0001. n = 5. Lumbar level Cresyl violet staining shows that, in contrast with small‐ and medium‐size neurons (interneurons and γMNs, left and center panels), large‐size neurons (αMNs, right panel) undergo progressive death first measured at 4.5 months. The values represent the average number of cells per ventral horn. For the small neurons (100–199 μm 2 ), there was no main effect, two‐way ANOVA for repeated measures for treatment group: F (1, 43) = 0.0017, P = 0.968, ns. For the medium‐sized neurons (200–299 μm 2 ) two‐way ANOVA for repeated measures for treatment group: showed no main effect F (1, 43) = 2.085, ns. For the large neurons (> 300 μm 2 ), two‐way ANOVA for repeated measures showed a significant main effect F (1, 43) = 59.99, P < 0.0001. Post hoc comparisons were performed by unpaired two‐sided t ‐test with equal SD comparing WT with En1‐ Het at each time point (* P < 0.05; ** P < 0.005; *** P < 0.0005; **** P < 0.0001). n = 5–6. Compared with WT mice, En1 ‐Het mice experience gradual strength loss. This loss is observed with the forepaw grip strength (left panel), the inverted grid test (center panel) and the hindlimb extensor reflex test (right panel). Strength loss is first observed between 2 and 3 months, thus before measurable αMN cell body loss. Two‐way ANOVA showed significant main effects for grip strength ( F (1, 136) = 19.18, P < 0.0001), inverted grid test ( F (1, 103) = 143.1, P < 0.0001), and extensor score ( F (1, 103) = 10.1, P < 0.0001). Comparisons were made by unpaired two‐sided t ‐test with equal SD comparing WT with En1‐ Het at each time point (* P < 0.05; ** P < 0.005; *** P < 0.0005; **** P < 0.0001). n = 4–20. Data information: The analysis of neuron number in (A), the direct comparison of Cresyl violet and ChAT in (C), and the longitudinal studies in (D and E) were performed once. Values are mean ± SD. Source data are available online for this figure.
Techniques Used: Expressing, Staining
Figure Legend Snippet: Analysis of EN1 amount in MNs at 3 months in WT and En1 ‐Het mice. EN1 content is reduced by about half in γMNs (left panel) and αMNs (right panel). EN1 was revealed by the LSBio antibody allowing for the visualization of endogenous EN1. Unpaired two‐sided t ‐test with equal SD (** P < 0.005; n = 5). Values are mean ± SD. Quantification of EN1 amount in γMNs and αMNs with the LSBio antibody at 3, 4.5 and 9 months in WT and En1 ‐Het mice. Values at 3 months correspond to the ones shown in panel A. At 4.5 and 9 months, the amount of EN1 in MNs is similar in En1 ‐Het and WT mice suggesting that, with time, each remaining MN receives a higher amount of EN1. Two‐way ANOVA showed a significant main effect for the γMNs ( F (1, 20) = 16.93, P = 0.0005) and αMNs ( F (1, 20) = 19.03, P = 0.0003). Unpaired two‐sided t ‐test with equal SD (* P < 0.05; n = 4–5). Data information: This experiment was performed once. Values are mean ± SD. Hypothetical representation of EN1 availability to αMNs in WT and Het mice. In the En1 ‐Het mouse, each V1 interneurons only provides half as much EN1 to the full population of αMNs at 3 months of age. At 4.5 months of age and later, half of the αMNs have been lost allowing each remaining αMN to receive its full complement of EN1 from the V1 interneurons.
Techniques Used:
Figure Legend Snippet: NMJs of En1‐ Het and WT mice show similar numbers of AChR clusters (left panel) and late‐occurring (15.5 months) decrease in endplate area (center panel) and percentage of perforated endplates (right panel). The number of AChR clusters seems to decrease between 2 and 3 months, but two‐way ANOVA showed no significant genotype effect ( F (1, 47) = 0.1291, ns). There was a significant main effect for endplate area ( F (1, 47) = 5.778, P = 0.0202) and for the percentage of perforated endplates ( F (1, 47) = 13.82, P = 0.0005). Post hoc analysis revealed significant genotype differences at 15.5 month of age. Unpaired two‐sided t ‐test with equal SD comparing WT with En1‐ Het at each time point (** P < 0.005). n = 4–8. Left panel illustrates the use of Alexa Fluor 488‐conjugated α‐bungarotoxin (α‐BTX, in green) and of neurofilament and synaptic vesicle glycoprotein antibodies (2H3 and SV2A, in red) to evaluate the percentage of fully occupied endplates (> 80% occupancy). The right panel shows that the % of fully occupied endplates decreases progressively in the En1 ‐Het mouse, starting between 3 and 4.5 months of age. Scale bar: 50 μm. Two‐way ANOVA showed a significant main effect ( F (1, 47) = 45.45, P < 0.0001). Unpaired two‐sided t ‐test with equal SD comparing WT with En1‐ Het at each time point (* P < 0.05; ** P < 0.005). n = 4–8. See details of analysis in the section. Data information: The longitudinal study in (A and B) was performed once. Values are mean ± SD. Source data are available online for this figure.
Techniques Used:
Figure Legend Snippet: RT–qPCR of RNA from the lumbar enlargement at 4.5 months of WT and En1 ‐Het mice and from WT muscle. En1 expression is absent from the muscle of WT mice. Unpaired two‐sided t ‐test with equal SD (*** P < 0.005; **** P < 0.0005; n = 4–5). Values are mean ± SD. Immunohistochemistry for EN1 protein (LSBio antibody, in green) shows its absence at the level of the NMJ (α‐BTX, in red). Scale bar = 50 μm. Data information: This experiment was done once. Values are mean ± SD.
Techniques Used: Quantitative RT-PCR, Expressing, Immunohistochemistry
Figure Legend Snippet: Experimental paradigm and structure of AAV8‐encoded constructs containing glial fibrillary acidic protein (GFAP) promoter for expression in astrocytes, Immunoglobulin K (IgK) signal peptide for secretion, anti‐ENGRAILED single‐chain antibody (scFvEN1), 6 myc tags (6xMyc), skipping P2A peptide, and enhanced Green Fluorescent Protein (eGFP). An inactive control antibody (scFvMUT) contains a cysteine to serine mutation that prevents disulfide bond formation between IgG chains, thus epitope recognition. The AAV8 was injected in 1‐month‐old WT mice, and the strength phenotypes were followed for 6 months before anatomical analysis. Analysis of 1‐month postinjection showing that scFv antibodies are expressed in astrocytes (white arrowhead) double‐stained for GFAP and Myc and exported (empty arrowhead). Scale bar: 50 μm. Left panel illustrates that expressing the scFvEN1, but not scFvMUT, abolishes EN1 staining by LSBio anti‐EN1 antibody in ventral horn ChAT+ cells and right panel quantifies this inhibition 1‐way ANOVA followed by Tukey corrected post hoc comparisons ( n = 5 mice per group, *** P < 0.0005, **** P < 0.0001). Scale bar: 100 μm. The three graphs illustrate how the WT antibody but not its mutated version leads to progressive strength decrease. Two‐way ANOVA showed significant main effects for grip strength ( F (2, 12) = 15.88, P < 0.0005), inverted grid ( F (2, 107) = 19.86, P < 0.0001), and extensor score ( F (2, 12) = 30.22, P < 0.0001) followed by Tukey corrected post hoc comparisons (* P < 0.05; ** P < 0.005; *** P < 0.0005; **** P < 0.0001). n = 5 per treatment. Six months following infection (7‐month‐old mice), extracellular EN1 neutralization does not modify the number of AChR clusters, nor the endplate surface area, nor the percentage of perforated endplates. In contrast, the percentage of fully occupied endplates is diminished (right end panel). 1‐way ANOVA followed by Tukey corrected post hoc comparisons (** P < 0.005). n = 5 per treatment. Six months following infection, extracellular EN1 neutralization does not globally modify the total neuron number of cells at the lumbar level (left panel). A separate analysis of small (100–199 μm 2 ), medium (200–299 μm 2 ), and large (>300 μm 2 ) neurons demonstrate a specific ( P < 0.0557) loss of the latter category (αMNs). 1‐way ANOVA followed by Tukey corrected post hoc comparisons. N = 5 per treatment. Data information: The extracellular neutralization study was performed twice. Values are mean ± SD. Source data are available online for this figure.
Techniques Used: Construct, Expressing, Mutagenesis, Injection, Staining, Inhibition, Infection, Neutralization
Figure Legend Snippet: Comparison between En1‐het mouse and scFvEN1 models. Data and graphs are from main figures (primarily Figs and ). WT mice injected with scFvEN1 show similar results to those obtained in the En 1‐Het mouse with a milder strength loss, a smaller decrease in the number of fully occupied endplates, and the specific loss of large‐size αMNs. At 7 months, scFvEN1 injected mice have a phenotype similar to 3‐month‐old En1 ‐Het mice.
Techniques Used: Injection
Figure Legend Snippet: Mice were tested for strength at 3 months of age, before the onset of αMN loss, but when strength has already decreased in En1 ‐het mice as measured in the forepaw grip strength, inverted grid, and extensor reflex tests (left side of each graph). The next day, the En1 ‐het mice were separated into two groups. One group received buffer and the other group recombinant hEN1 (1 μg in 5 μl), injected at the L5 level. One and a half months later (4.5 months of age) En1 ‐het mice injected with hEN1 have recovered normal strength, in contrast with noninjected mice or mice injected with buffer. Unpaired two‐sided t ‐test used at 3 months of age. **** P < 0.0001. For 4.5‐month comparisons, 1‐way ANOVA followed by Tukey corrected post hoc comparisons. *** P < 0.0005; **** P < 0.0001. n = 9–31. At 4.5 months, following hEN1 injection at 3 months, the percentage of fully occupied endplates and the number of αMNs are not significantly different from control values. 1‐way ANOVA followed by Tukey corrected post hoc comparisons. *** P < 0.0005; **** P < 0.0001. n = 5–21. Data information: The weakness and reversal with hEN1 and the neuroprotection were replicated in five independent experiments. Values are mean ± SD. Source data are available online for this figure.
Techniques Used: Recombinant, Injection
Figure Legend Snippet: Top left panel shows the single injection protocol whereby hEN1 is injected at 3 months (1 μg in 5 μl) intrathecally at the L5 level and mouse behavior followed for 24 weeks. The 3 time‐course graphs demonstrate that a single injection restores strength measured by the tests of grip strength, time on the inverted grid and extensor reflex and that this effect lasts for 12 weeks. After 12 weeks, strength decreases progressively but, even after 24 weeks, remains superior to that of untreated En1 ‐Het mice. At 24 weeks, the % of fully occupied endplates is inferior to that of WT mice, but superior to that of noninjected En1 ‐Het mice. The same holds true for the number of αMNs. Two‐way ANOVA revealed significant main effects for grip strength ( F (1, 76) = 143.6, P < 0.0001), inverted grid ( F (1, 76) = 128.6, P < 0.0001), and extensor score ( F (1, 76) = 34.91, P < 0.0001). At the different times, the groups were compared by unpaired t‐test with equal variances comparing WT with En1‐ Het injected at each time point. (* P < 0.05; ** P < 0.005; *** P < 0.0005; **** P < 0.0001). For the endplate analysis and αMNs, groups were compared by 1‐way ANOVA followed by Tukey corrected post hoc comparisons (* P < 0.05; ** P < 0.005; *** P < 0.0005; **** P < 0.0001). n = 4–10. Based on the results shown in A, a new experiment was performed with a second injection 12 weeks after the first injection at 3 months of age. Again, the injection at 3 months of age restored strength and in mice receiving the second injection strength was maintained an additional 10 weeks or more compared with mice receiving a single injection. The three strength graphs demonstrate a positive effect of the second injection with values intermediate between those measured in WT mice and En1‐Het mice with a single injection. The percentage of fully occupied endplates and the number of αMNs are back to wild‐type values in En1 ‐Het mice injected twice. Two‐way ANOVA revealed significant main effects for grip strength ( F (2, 81) = 25.47, P < 0.0001), inverted grid ( F (2, 91) = 51.96, P < 0.0001), and extensor score ( F (2, 104) = 30.42, P < 0.0001). At all times, groups were compared by unpaired t‐test with equal variances through 12 weeks. After, the groups were compared by Tukey corrected post hoc comparisons (* P < 0.05; ** P < 0.005; *** P < 0.0005; **** P < 0.0001). For the endplate analysis and αMNs, groups were compared by 1‐way ANOVA followed by Tukey corrected post hoc comparisons (* P < 0.05; ** P < 0.005; *** P < 0.0005; **** P < 0.0001). n = 4–10. Data information: The single injection and two injection time‐course studies were performed once each. Values are mean ± SD. Source data are available online for this figure.
Techniques Used: Injection
Figure Legend Snippet: Top left panel shows that 24 h after intrathecal injection (1 μg in 5 μl) at the L5 level of 2‐month‐old mice, hEN1 (red) can be primarily visualized in ventral horn ChAT+ cells (green). Arrowheads show hEN1 internalized by MNs. Scale bar: 100 μm. Top right panels show the progressive accumulation and clearance of hEN1 in ventral horn MNs, with a peak between 6 and 24 h. EN1 was revealed by the 86/8 antibody allowing for the visualization of exogenous EN1 only (scale bar: 100 μm). Bottom panels show the quantification of EN1 in γMNs and αMNs with the 86/8 (two left panels) and the LSBio (two right panels) antibodies. Since the LSBio sees both endogenous and exogenous EN1, the increase is only threefold, but qualitatively, the results are very similar, demonstrating rapid internalization and clearance of the exogenous protein and allowing one to calculate a half‐life of 24 h. One‐way ANOVA followed by Tukey corrected post hoc comparisons (* P < 0.05; ** P < 0.005; *** P < 0.0005). When not significant, P ‐values are shown. n = 3. Values are mean ± SD. Data information: The internalization experiments were performed once with each antibody. Left panel gives examples of putative glycosaminoglycan (GAG)‐binding domain in 11 homeoprotein transcription factors. Based on the alignment and on published work on OTX2 (Beurdeley et al , ) and EN2 (preprint: Cardon et al , ), a putative EN1 GAG‐binding domain (RK‐EN1) was designed. Middle panel quantifies the inhibitory effect of RK‐EN1 on hEN1 capture (86/8 antibody) by ChAT+ cells demonstrating that RK‐EN1 in a 1 to 20 ratio reduces the % of EN1‐positive MNs (ChAT+) from 50 to less than 10%. The right panel demonstrates that this inhibitory activity is not shared by the mutant AA peptide or by a scrambled (Scr) peptide. Unpaired two‐sided t ‐test with equal SD (** P < 0.005; *** P < 0.0005). n = 2–5. Data information: The GAG competition experiment was performed twice as described in the text. Values are mean ± SD except for conditions with two observations for which both data points are shown. Source data are available online for this figure.
Techniques Used: Injection, Binding Assay, Activity Assay, Mutagenesis
Figure Legend Snippet: The search for genes differentially expressed in WT and En1 ‐Het mDA neurons and expressed in MNs, thus putative non‐cell‐autonomous EN1 targets in MNs, allowed for the identification of 402 genes (after pathway selection). These genes were investigated for an interaction with genes mutated in the main 4 familial ALS forms. Among them, p62/SQSTM1 ( p62 ) expression is upregulated in the SNpc (RNA‐seq) and in MNs of En1 ‐Het mice. Immunohistochemical staining shows the presence of high amounts of p62/SQSTM1 in ChAT+ cell bodies of 3‐month‐old mice. Scale bar: 50 μm. Intensity measurements demonstrate that the mean of p62/SQSTM1 expression increases with age in WT γMNs (left) and αMNs (right). However, comparing WT and En1 ‐Het shows a significant difference only at 3 months and not later. Unpaired two‐sided t ‐test. (* P < 0.05; ** P < 0.005; *** P < 0.0005, **** P < 0.0001). Data information: This experiment was done once. Values are mean ± SD. Between 151 and 1,215 neurons and 3–5 mice were analyzed for each condition. Mean intensity of p62/SQSTM1 expression is increased in γMNs (left) and αMNs (right) in mice expressing scFvEN1 6 months after virus injection (7‐month‐old mice) demonstrating that EN1 extracellular neutralization increases p62/SQSTM1 expression. Expression of the mutated antibody (scFvMUT) does not increase p62/SQSTM1 expression. Unpaired two‐sided t ‐test. (* P < 0.05; ** P < 0.005; *** P < 0.0005, **** P < 0.0001). Data information: This experiment was performed once. Values are mean ± SD. Between 448 and 759 neurons and 5 mice were analyzed for each condition. Source data are available online for this figure.
Techniques Used: Selection, Expressing, RNA Sequencing Assay, Immunohistochemical staining, Staining, Injection, Neutralization
Figure Legend Snippet: Left panel: Injection and analysis protocol. Right panel: muscle strength analysis demonstrating that hEN1 injection at 1 month prevents muscular strength decrease observed in 3‐month‐old En1‐Het mice. One‐way ANOVA followed by two‐sided t ‐test. (* P < 0.05, **** P < 0.0001). N = 6–10. Data information: This experiment was performed once. Values are mean ± SD. Left panel: Increased p62/SQSTM1 staining in 3‐month‐old ChAT+ MNs from control En1 ‐Het is abolished by hEN1 injection at 1 month. Right panel: quantification of p62/SQSTM1 staining in γMNs and αMNs of control and hEN1‐injected 3‐month‐old En1 ‐het mice. One‐way ANOVA followed by two‐sided t ‐test. (** P < 0.01, **** P < 0.0001). Data information: This experiment was performed once. Values are mean ± SD. Between 111 and 303 neurons and 4–5 mice were analyzed for each condition. Source data are available online for this figure.
Techniques Used: Injection, Staining
Figure Legend Snippet: EN1 transcribed and synthesized in V1 (pink) has a cell‐autonomous activity in these cells contributing to the expression of several V1 factors (FA, FB, …) that may signal to MNs (yellow) and other cell types (blue). All the latter F factors do not necessarily require EN1 activity. EN1 after its secretion by V1 interneurons is preferentially internalized by MNs (fat red arrow) and less by other cell types (thin red arrow), if at all. These other cell types express other F Factors (FX, FY, …) which are secreted and are, or not, under non‐cell‐autonomous EN1 activity. As a result, MNs experience the signaling activity of F factors (possibly EN1‐dependent as in the scheme, but not necessarily so) and internalize EN1. Following internalization, EN1 can work alone or in synergy with the F factors to regulate transcription, translation, and chromatin conformation within MNs.
Techniques Used: Synthesized, Activity Assay, Expressing
Figure Legend Snippet:
Techniques Used: Multiplex Assay, RNA Extraction, BIA-KA, Plasmid Preparation, Software


